Biotechnology Daily
more-
Roche drops solid tumor option, intensifying the squeeze on SQZ
The squeeze on SQZ Biotechnologies is getting tighter. After 12 months of value destruction, the…
New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy
With updated FDA nod, BD aims to revive beleaguered Alaris infusion pumps
To prevent cancer metastasis, prevent protein migration, new study suggests
Amgen’s lupus bets continue to flounder, even those on the Horizon
Market Watch
more-
Weekly Market Review – September 30, 2023
Stock Markets Several geopolitical issues weighed on investor sentiment this week, including higher oil prices…
Bio Business News
more
Humanigen mulls bankruptcy after reverse merger falls through
Humanigen is running out of options. Talks over a reverse…
Heron lays off 25% of employees and renegotiates vendor contracts to save money
Just more than a year after letting go of a…
Roche signs onto Alnylam’s midstage hypertension med for $310M upfront
Roche is hitching its wagon to Alnylam’s midstage hypertension med,…
World News
more
Stocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Weekly Market Review – September 30, 2023
Roche drops solid tumor option, intensifying the squeeze on SQZ
New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy
With updated FDA nod, BD aims to revive beleaguered Alaris infusion pumps
To prevent cancer metastasis, prevent protein migration, new study suggests
Humanigen mulls bankruptcy after reverse merger falls through
Heron lays off 25% of employees and renegotiates vendor contracts to save money
Roche signs onto Alnylam’s midstage hypertension med for $310M upfront
Philips ekes out a profit for the first time in over a year, though orders continue to drop
Tesla’s quarterly deliveries, profit seen lower by Citi